Date: 2018-04-17
Type of information: Nomination
Compound: president - member of the board of directors
Company: Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On April 17, 2018, Akcea Therapeutics announced that, following the close of the transaction licensing Akcea the exclusive, worldwide rights to inotersen and AKCEA-TTR-LRx, Sarah Boyce has joined Akcea as president and a member of the Akcea board of directors. As president, Ms. Boyce will serve on Akcea’s executive team and will lead all global commercialization. Akcea is focused on developing and commercializing drugs to treat patients with serious and rare diseases, including inotersen and volanesorsen.
- Ms. Boyce brings to Akcea extensive, global experience in the life sciences industry where she established organizations from inception around the world and built high performing teams. Ms. Boyce also led the launches of multiple, billion-dollar drugs, including Soliris®, Tasigna®, Glivec® and Herceptin®.
- Ms. Boyce most recently served as the chief business officer at Ionis Pharmaceuticals where she was responsible for business development, alliance management, investor relations, corporate communications, competitive intelligence and patient advocacy. Prior to joining Ionis in January 2015, Ms. Boyce held multiple executive level roles at large pharma and biotech companies including Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.
Financial terms:
Latest news:
Is general: Yes
